References
- Wong J, Smith LB, Magun EA, Engstrom T, Kelley-Howard K, Jandhyala DM, Thorpe CM, Magun BE, Wood LJ. Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin. Cancer Biol Ther 2013; 14:56 - 63; http://dx.doi.org/10.4161/cbt.22628; PMID: 23114643
- Sauter KA, Wood LJ, Wong J, Iordanov M, Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther 2011; 11:1008 - 16; http://dx.doi.org/10.4161/cbt.11.12.15540; PMID: 21464611
- Baldassare JJ, Bi Y, Bellone CJ. The role of p38 mitogen-activated protein kinase in IL-1 beta transcription. J Immunol 1999; 162:5367 - 73; PMID: 10228013
- Sauter KA, Magun EA, Iordanov MS, Magun BE. ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells. Cancer Biol Ther 2010; 10:258 - 66; http://dx.doi.org/10.4161/cbt.10.3.12367; PMID: 20559024
- Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26:127 - 32; http://dx.doi.org/10.1038/nbt1358; PMID: 18183025
- Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, Mestan J, Trappe J, Wartmann M, Fabbro D. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010; 1804:445 - 53; http://dx.doi.org/10.1016/j.bbapap.2009.11.008; PMID: 19922818
- Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29:1046 - 51; http://dx.doi.org/10.1038/nbt.1990; PMID: 22037378
- Villar VH, Vögler O, Martínez-Serra J, Ramos R, Calabuig-Fariñas S, Gutiérrez A, Barceló F, Martín-Broto J, Alemany R. Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas. PLoS One 2012; 7:e37735; http://dx.doi.org/10.1371/journal.pone.0037735; PMID: 22662203
- Abou-Alfa GK, Saltz LB. Doxorubicin and sorafenib for treatment of advanced hepatocellular cancer. Gastroenterology 2011; 141:e19 - 20, author reply e20-1; http://dx.doi.org/10.1053/j.gastro.2011.04.063; PMID: 21794834
- Hamed H, Mitchell C, Park MA, Hanna D, Martin AP, Harrison B, Hawkins W, Curiel DA, Fisher PB, Grant S, et al. Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo. Cancer Biol Ther 2008; 7:587 - 93; http://dx.doi.org/10.4161/cbt.7.4.5543; PMID: 18379195
- He G, Karin MNF. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011; 21:159 - 68; http://dx.doi.org/10.1038/cr.2010.183; PMID: 21187858